StoxGud Sign in
50

Viyash Scientific Limited

NSE: VIYASH · Healthcare

₹229.48-1.43%06 Nov 2026

Ask the data

Instant answers about Viyash Scientific Limited — computed from its filings, no language model
Market cap₹10,025 cr
Current price₹229.48
High / Low₹294 / ₹180
P/E58.6
P/B3.44
Book value₹66.6
ROE5.9%
ROCE11.8%
Debt / equity0.15
Dividend yield0.05%
EPS (TTM)₹3.92
Face value₹2

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin
showing latest 6 of 9 periods
FY18FY19FY20FY21FY22FY23FY24FY25FY26
Revenue8491,0391,1791,3621,4131,4211,3701,5513,420
EBITDA831251702121091261162653
Operating margin9.8%12.0%14.4%15.6%7.7%0.8%4.5%10.4%19.1%
Interest333336241636486169
Depreciation4142515151566266234
Profit before tax24599413753-138-5544349
Tax13212328-16-2512124
Net profit42549709541-121-3622177
EPS ₹17.402.002.873.871.67-4.88-1.440.884.09
Operating cash flow————31173183323
Capex————32863139135
Dividend paid————120025
Total assets—————1,5291,5401,6024,628
Equity—————6996577042,911

Quarterly performance

last 34 quarters · ₹ crore
showing latest 8 of 34 periods
MAR '18JUN '18SEP '18DEC '18MAR '19JUN '19SEP '19DEC '19MAR '20JUN '20SEP '20DEC '20MAR '21JUN '21SEP '21DEC '21MAR '22JUN '22SEP '22DEC '22MAR '23JUN '23SEP '23DEC '23MAR '24JUN '24SEP '24DEC '24MAR '25JUN '25SEP '25DEC '25MAR '26JUN '26
Revenue233235252271282278284316301310346358362321351358384341338375367333346329361390369391402441424858920946
Operating profit30232836393837504551566643202036332310-3-8152232423934465256176184178
Operating margin13.0%9.6%11.0%13.2%13.8%13.8%13.1%15.8%14.9%16.4%16.3%18.5%12.0%6.3%5.6%10.1%8.7%0.6%0.9%2.8%-0.9%-2.5%4.4%6.8%8.9%10.8%10.6%8.8%11.5%11.8%13.1%20.5%20.0%18.8%
Other income322221612233131441132125435624214168
Interest108889981098763333678101110131312161415151414171513
Depreciation9101011111212131313131213131313121313141514151516161717161515596062
Profit before tax1371218221923282432295129742419-20-18-10-89-56-313128816262773125112
Tax42-3304-246781255-1059-5-13-04-214-91322688255933
Net profit40031513171121201721213721114179-14-4-9-94-35-88-176391415385266
EPS ₹16.500.140.630.540.710.470.880.830.690.850.861.520.840.040.580.690.36-0.57-0.15-0.36-3.77-1.40-0.340.33-0.040.260.100.140.370.570.590.891.201.51
Revenue YoY————21.1%18.2%12.9%17.0%6.6%11.6%21.8%13.2%20.4%3.3%1.2%-0.0%6.0%6.5%-3.7%4.8%-4.4%-2.4%2.5%-12.2%-1.5%17.1%6.6%18.7%11.2%13.1%15.0%119.6%129.0%114.4%
Profit YoY————-95.7%249.4%39.8%55.8%-1.5%82.5%-0.1%83.4%22.4%-95.8%-32.7%-54.0%-56.6%-1714.9%-126.2%-151.8%-1144.3%——————-58.4%—119.8%132.5%1017.4%459.1%360.3%

Earlier results (standalone, Sep '07 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

Viyash Scientific Limited reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

FY09†FY12†FY13†FY14†FY15†FY16†FY17†
Revenue106332314445442397388
Operating profit1235-165573713
Operating margin11.2%10.5%-5.1%1.2%12.8%9.3%3.5%
Other income21212771220
Interest428323947168
Depreciation4212727262425
Profit before tax6-2-63-114437-0
Tax2-4-80200
Net profit41-54-114417-0

Quarters

showing latest 8 of 40 periods
SEP '07†DEC '07†MAR '08†JUN '08†SEP '08†DEC '08†MAR '09†JUN '09†SEP '09†DEC '09†JUN '10†SEP '10†DEC '10†JUN '11†SEP '11†DEC '11†MAR '12†JUN '12†SEP '12†DEC '12†MAR '13†JUN '13†SEP '13†DEC '13†MAR '14†JUN '14†SEP '14†DEC '14†MAR '15†JUN '15†SEP '15†DEC '15†MAR '16†JUN '16†SEP '16†DEC '16†MAR '17†JUN '17†SEP '17†DEC '17†
Revenue16182323282925267765637168698975100726383971141141141041101151111061081128691879410510211211027
Operating profit3-022433425129121470621-4-21-1156-0-53102320138882245911-2
Operating margin18.5%-0.8%9.3%7.6%14.1%9.5%13.3%16.1%32.3%18.4%15.1%17.0%20.0%10.5%0.5%8.4%21.2%-5.7%-3.6%1.4%-11.3%4.1%5.5%-0.4%-5.0%3.1%8.4%20.9%19.3%12.0%7.1%9.4%8.7%2.3%2.4%3.7%5.2%7.7%9.8%-6.6%
Other income00-0001101113161131101011244111333345475104
Interest01111123654567777778109910111313121073342222220
Depreciation0111111133354457567686778867655686667671
Profit before tax2-111311114531052-10-612-16-6-12-28-9-10-26-69-124727-19423-2-2-1-136122
Tax0-00010005112110-3-3-1-2-1-40000000200000000006
Net profit2-10021111043940-10-314-15-4-11-24-9-10-26-69-124727-20423-2-2-1-13612-4
EPS ₹1.49-1.030.380.371.630.730.630.554.521.661.243.901.840.23-4.79-1.316.54-6.92-1.91-4.86-10.05-3.86-3.93-9.89-25.31-4.5717.069.35-6.641.090.580.57-0.07-0.08-0.03-0.030.130.230.50-0.18
Revenue YoY————82.3%62.4%8.8%11.4%172.0%121.9%142.0%-8.2%5.0%9.3%26.0%10.2%—4.7%-29.4%10.4%-3.2%58.2%81.3%37.4%7.4%-3.4%0.8%-2.4%2.1%-1.4%-2.7%-22.7%-14.0%-20.0%-16.3%22.6%12.5%29.0%17.1%-74.6%
Profit YoY————17.6%—62.8%48.8%432.8%335.8%331.1%-10.8%14.2%-81.0%-222.8%-171.0%—-3136.0%——-266.4%—————————-94.8%-90.8%—-150.4%-127.0%-126.9%————

Returns & margins

trailing-twelve-month, per quarter
showing latest 8 of 31 periods
DEC '18MAR '19JUN '19SEP '19DEC '19MAR '20JUN '20SEP '20DEC '20MAR '21JUN '21SEP '21DEC '21MAR '22JUN '22SEP '22DEC '22MAR '23JUN '23SEP '23DEC '23MAR '24JUN '24SEP '24DEC '24MAR '25JUN '25SEP '25DEC '25MAR '26JUN '26
ROE———————————————1.1%-2.4%-17.2%-20.2%-23.1%-20.3%-5.5%0.8%3.0%2.3%3.6%4.7%5.2%9.5%4.1%5.9%
ROCE———————————————2.6%0.2%-9.2%-12.1%-10.9%-9.5%-0.6%6.0%7.0%7.8%9.1%10.1%10.7%15.9%9.3%11.8%
Net margin43.5%4.7%5.3%5.6%6.0%5.9%6.6%6.2%7.3%7.3%5.8%5.2%3.8%2.9%1.8%0.6%-1.2%-8.5%-10.0%-10.3%-9.3%-2.6%0.4%1.4%1.0%1.7%2.1%2.5%3.6%4.5%5.4%
EBITDA margin11.7%12.0%13.0%13.5%14.2%14.4%15.1%15.9%16.6%15.8%13.4%10.7%8.6%7.7%6.4%5.2%3.4%0.8%0.1%1.0%1.9%4.5%7.8%9.4%9.8%10.4%10.7%11.4%15.5%17.7%18.9%
Debt / equity———————————————0.520.520.570.570.660.660.690.690.660.660.630.630.560.560.150.15
Interest coverage2.482.803.083.393.593.634.114.355.486.816.926.845.944.392.361.200.06-2.84-3.40-2.61-2.14-0.141.241.431.531.731.992.333.395.266.90
Asset turnover———————————————0.950.960.930.920.950.920.890.930.930.970.971.000.961.230.570.68

Balance sheet

equity vs borrowings over time · ₹ crore
showing latest 6 of 8 periods
SEP '22MAR '23SEP '23MAR '24SEP '24MAR '25SEP '25MAR '26
Share capital5050505050505087
Other equity / reserves6886495826076306547592,824
Total equity7386996326576807048092,911
Borrowings381398419451452446456436
Current liabilities499526602627489505504946
Non-current liabilities213254216200331327335568
Total assets1,4931,5291,5011,5401,5621,6021,7264,628
Property, plant & equipment3123013002492412322971,138
Capital work-in-progress455135111215569
Investments00141000
Inventories372346326346361385418803
Receivables3093413093363413634231,045
Cash & equivalents39425965686371256

Cash flow

annual · ₹ crore · line = free cash flow
FY22FY23FY24FY25FY26
Cash from operations31173183323
Cash from investing-94-65-6-25-84
Cash from financing6732-1-61-123
Capex32863139135
Free cash flow-2-69-044188
Dividends paid120025

Where the assets sit

Mar '26 · ₹ crore
Fixed assets (PPE)
₹1,138 cr25%
CWIP
₹69 cr1%
Investments
₹0 cr0%
Inventories
₹803 cr17%
Receivables
₹1,045 cr23%
Cash & equivalents
₹256 cr6%
Other assets
₹1,318 cr28%

Peer comparison

largest in Healthcare · this company in bold
CompanyMarket cap ₹crPriceP/EP/BROE
Sun Pharmaceutical Industries Ltd.4,46,2701,860.0040.75.0012.3%
Divi's Laboratories Ltd.2,73,49310,320.5093.516.3217.5%
Torrent Pharmaceuticals Ltd.1,80,6714,750.0085.19.8311.6%
Laurus Labs Ltd.1,26,4302,340.0094.420.8622.1%
Apollo Hospitals Enterprise Ltd.1,21,4538,446.0054.211.4521.1%
Zydus Lifesciences Ltd.1,19,5501,197.9028.64.3015.0%
Dr. Reddy's Laboratories Ltd.1,14,6461,373.0040.92.957.2%
Cipla Ltd.1,13,9881,411.0039.33.228.2%
Mankind Pharma Ltd.1,04,9022,540.0046.75.9712.8%
Aurobindo Pharma Ltd.1,03,5721,800.0026.02.6310.1%
Viyash Scientific Limited10,025229.4858.63.445.9%

StoxGud checklist: Neutral setup · 5/10

  • Price above 50-day average
  • Price above 200-day average
  • 50-day average above 200-day (uptrend)
  • RSI in healthy 40–70 zone
  • Positive 1-year return
  • Return on equity above 15%
  • Debt to equity below 1
  • Revenue growing year on year
  • Net profit margin above 10%
  • P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-4.7%
6 months+3.5%
1 year+7.9%
3Y CAGR+31.5%
5Y CAGR+4.0%
10Y CAGR+6.5%
50-day avg₹239.60
200-day avg₹234.19
RSI (14)52

FAQs

What is the share price of Viyash Scientific Limited?

Viyash Scientific Limited (VIYASH) closed at ₹229.48 on NSE on 06 Nov 2026.

What is the market cap of Viyash Scientific Limited?

₹10,025 crore at the latest close.

What is the P/E ratio of Viyash Scientific Limited?

58.6, on trailing-twelve-month earnings from its filings.

How fast is Viyash Scientific Limited growing?

Viyash Scientific Limited: revenue has compounded at 34.0% a year over three years. Latest-quarter revenue is up 114.4% year on year, profit up 360.3%.

How profitable is Viyash Scientific Limited?

On a trailing-twelve-month basis return on equity is 5.9%, return on capital employed 11.8%, operating margin 18.9%, net margin 5.4%.

How much debt does Viyash Scientific Limited have?

Viyash Scientific Limited is lightly geared: debt to equity is 0.15 with borrowings of ₹436 cr against cash of ₹256 cr (balance sheet of 2026-03-31). Operating profit covers interest 6.9 times.

Financials parsed from Viyash Scientific Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.